Introduction
============

Esophageal cancer is one of the most common malignant tumors. It is associated with high mortality rates and is the sixth leading cause of cancer-related death in the world ([@b1-ol-0-0-11709],[@b2-ol-0-0-11709]). China has a high incidence of esophageal cancer and the highest morbidity and mortality rates in the world. Approximately one-half of new cases each year are recorded in China, and the majority is squamous cell carcinoma ([@b3-ol-0-0-11709]--[@b5-ol-0-0-11709]). The incidence of esophageal cancer exhibits significant regional and ethnic differences ([@b6-ol-0-0-11709]). Despite great progress in the diagnosis and treatment of esophageal cancer, the 5-year survival rate is still poor ([@b7-ol-0-0-11709]). Therefore, identifying biomarkers related to the occurrence, development and prognosis of esophageal cancer is important for early diagnosis and treatment, as well as for finding new targets and treatment methods.

Tumor protein 53 (*TP53*) is a recognized tumor suppressor gene located on chromosome 17q13.1. The *TP53* gene plays an important role in regulating the cell cycle, apoptosis and DNA damage repair ([@b8-ol-0-0-11709],[@b9-ol-0-0-11709]). Wild-type *TP53* can inhibit the cell cycle and activate apoptosis-related genes that induce apoptosis and regulate cell proliferation ([@b10-ol-0-0-11709]). Mutations in *TP53* can lead to the loss of these functions, inducing uncontrolled cell growth and the promotion of tumor development ([@b11-ol-0-0-11709],[@b12-ol-0-0-11709]). These *TP53* abnormalities may lead to DNA damage and subsequent aneuploidy.

The *TP53* gene mutation is the most common gene alteration in many tumors, including esophageal cancer. It also plays an important role in the occurrence and development of esophageal cancer ([@b13-ol-0-0-11709],[@b14-ol-0-0-11709]). Although the biological significance of *TP53* gene mutation is well characterized, its clinical significance in esophageal cancer remains controversial, especially as a prognostic biomarker. Previous studies demonstrated that p53 was highly expressed in esophageal cancer tissue and was associated with tumor malignancy ([@b15-ol-0-0-11709]--[@b17-ol-0-0-11709]). However, other previous studies reported that the expression of p53 protein had no significant association with the prognosis of esophageal cancer ([@b18-ol-0-0-11709],[@b19-ol-0-0-11709]). The detection of mutant p53 protein by immunohistochemistry (IHC) has some limitations. For example, viral infection, stress and the regulation of other proteins can also change the aggregation of p53 protein ([@b20-ol-0-0-11709]). Therefore, the overexpression of p53 does not always indicate a mutation in the *TP53* gene. Similarly, *TP53* mutation does not always lead to the accumulation of p53 protein in cells. This characteristic of the *TP53* gene limits the use of IHC in *TP53* gene research, which may be the cause of the conflicting results in the study of *TP53* in esophageal cancer.

Fluorescence *in situ* hybridization (FISH) is a molecular pathological method with high sensitivity and specificity, which uses specific DNA probes to detect chromosomal aberrations, as well as gene deletion and amplification ([@b21-ol-0-0-11709],[@b22-ol-0-0-11709]). It has been reported that deletion of the *TP53* gene plays an important role in the occurrence and development of esophageal cancer ([@b23-ol-0-0-11709],[@b24-ol-0-0-11709]). At present, to the best of the authors\' knowledge, associations between the IHC and FISH methods in the detection of *TP53* in multi-ethnic esophageal cancer have not been reported.

In the present study, IHC and FISH were used to analyze the role of *TP53* in the occurrence, development and adverse prognosis of esophageal cancer in different ethnic groups in Xinjiang (multi-ethnic group). In addition, a tissue microarray (TMA) group from different regions (including other high-incidence areas in China, where the etiology of esophageal cancer is different from Xinjiang province owing to the difference of diet and living habits) was used to validate the results. The complementarity, clinical practicability and the accuracy of the detection of *TP53* abnormality in esophageal cancer using these two methods were evaluated.

Patients and methods
====================

### Patients and samples

A total of 369 paraffin-embedded esophageal squamous cell carcinoma (ESCC) and 187 matched adjacent normal tissue specimens from patients of Kazakh, Uygur and Han ethnicities, who underwent radical surgery between January 2012 and December 2014 in The Thoracic Surgery Department of The First Affiliated Hospital of Xinjiang Medical University were collected. Glass slides with 4-µm tissue sections were produced from the paraffin-embedded blocks for IHC and FISH detection. Among the 369 patients, 257 were male and 112 were female, with an average age of 60.8 years (range, 37--83 years). With regards to differentiation, 77 cases were poorly differentiated, 196 cases were moderately differentiated and 96 cases were highly differentiated. Lymph node metastasis was detected in 158 cases, while 211 cases exhibited no lymph node metastasis. With regards to TNM stage ([@b25-ol-0-0-11709]), there were 30 cases with stage I, 119 cases with stage II and 220 cases with stage III. None of the patients had received radiotherapy, chemotherapy or any other cancer treatment before surgery. Complete follow-up data were available for 214 patients. The survival time was measured from the date of surgery to death or the last follow-up date. All experiments were approved by The Ethics Committee of The First Affiliated Hospital of Xinjiang Medical University, and written informed consent was obtained from all participants.

TMA was carried out by Shanghai Core Super Biotechnology Co., Ltd. There were 117 cases of ESCC with one core (diameter, 1.5 mm) for each tumor sample, including 87 males and 30 females, with an average age of 64.7 years (range, 39--82 years). With regards to differentiation, 32 were poorly differentiated, 59 were moderately differentiated and 26 were highly differentiated. There were 63 cases of lymph node metastasis. Furthermore, there were 7 cases with stage I, 49 cases with stage II, 57 cases with stage III and 4 cases with stage IV. The patients received radical surgery between January 2006 and October 2008, and complete follow-up data were available for 100 patients. The follow-up period was terminated in September 2019 and the total follow-up time was 5.8--7.8 years. In addition, 3 normal esophageal mucosa tissues, 97 adjacent normal tissues, 13 precancerous lesions and 9 metastatic lesions of ESCC were included in the TMA.

### IHC

Tumor samples were fixed with 10% neutral formalin for 12 h in room temperature, then replaced with new 10% neutral formalin for 24 h, embedded in paraffin, and sectioned into 4-µm-thick slices. IHC was performed as previously described ([@b15-ol-0-0-11709]). In brief, the tissue sections were incubated at 60°C for 1 h, then dewaxed and hydrated in xylol and gradient alcohol, and placed in 3% hydrogen peroxide solution for 10 min to remove endogenous peroxidase. The antigen retrieval step was performed by heating in a microwave oven at 95°C for 10 min in citrate buffer (pH 7.0). After cooling at room temperature, the sections were treated with mouse anti-human p53 monoclonal antibody (1:400; P 5813, Sigma-Aldrich; Merck KGaA) and incubated at 4°C overnight in a moist chamber. The sections were then treated with universal secondary antibody (ready to use, PV-6000, Beijing Zhongshan Jinqiao Biotechnology Co., Ltd) and incubated at 37°C for 25 min. Finally, DAB and hematoxylin were used to visualize immunoreactivity and for counterstaining, respectively. Both steps were performed at room temperature for 3 min. Retrospective tissue sections of confirmed breast cancer were provided by the Department of Pathology (The First Affiliated Hospital of Xinjiang Medical University) were used as the positive control. Informed consent was provided by patients at the time of tissue collection. PBS was used as the negative control instead of primary antibody.

The results were independently evaluated by two pathologists in a blind manner. A total of five high-power fields of vision (magnification, ×20) were observed under a light microscope (Leica DM 3000B; Lecia Microsystems GmbH) on each slide and 100 tumor cells were counted in each field, and the percentage of positive cells were calculated. Primary lesions with evident nuclear staining in \>10% tumor cells, including the basal cell layer of the mucosa that had corresponding p53 characteristic positive staining, was determined as positive. Weak staining limited to basal cells was considered to be negative ([@b26-ol-0-0-11709]).

### FISH

FISH was performed using a mixture of red-labeled *TP53* and green-labeled chromosome 17 centromere control probe (Cytocell Ltd.). The amount of p53 probe is 40--50 ng/test and 159 kb in length covers the whole *TP53* gene, and amount of control probe is 60--75 ng/test, respectively. Briefly, tissue samples were incubated at 60°C for 2 h, then dewaxed with xylol, hydrated with gradient ethanol solution, and washed with ultra-pure water. The slides were then incubated at 80°C in Vysis pretreatment solution (Vysis, Inc.; Abbot Pharmaceutical, Co., Ltd.) for 15 min. After washing with ultra-pure water, the slides were incubated in Vysis protease I solution (Vysis, Inc.; Abbot Pharmaceutical, Co., Ltd.) at 37°C for 10 min, and then dehydrated in a series of cold ethanol solutions (70, 80, 90 and 100%, each for 2 min) after washing with ultra-pure water. Following this, 10 µl of the hybrid mixture was added and the glass slides were covered with rubber cement. Slides were then denatured at 75°C for 5 min and hybridized at 37°C overnight, using a hybridization instrument. The next day, the slides were washed with 2X SSC (ID Labs™ Inc. Biotechnology, <http://www.lookbio.com/>) solution for 2 min at 72°C, then at room temperature for 1 min. Subsequently, 5 µl DAPI was applied to each spot and covered with a cover slip. A confocal laser scanning microscope (Leica Microsystems GmbH, magnification, ×100) was used for imaging and analysis. The length of stimulated luminescence were: Blue (DAPI) 405 nm, green (FITC) 488nm, red (Texas Red) 561 nm, respectively.

For analysis, ≥100 non-overlapping and complete nuclei with fluorescent signals were counted, and the results were calculated according to the percentage of nuclei with signal changes. There are two red and two green signals in normal nuclei. Samples with \>30% of tumor nuclei with either none or only one red signal per probe were determined to indicate *TP53* deletion.

### Statistical analysis

Data were analyzed using SPSS 20.0 software (IBM Corp.). The χ^2^ test and Fisher\'s exact test were conducted. Survival analysis was performed using Kaplan-Meier and log-rank tests. Univariate and multivariate analyses were conducted by Cox regression. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Association of p53 protein expression with clinicopathological factors

The positive expression rates of p53 protein in cancer tissue and adjacent normal tissue were 54.5% (201/369) and 1.1% (2/187), respectively, and this difference was statistically significant (P\<0.001; [Fig. 1](#f1-ol-0-0-11709){ref-type="fig"}; [Table I](#tI-ol-0-0-11709){ref-type="table"}). The expression of p53 protein was significantly associated with sex (P=0.026) and tumor differentiation (P=0.032). There were no significant associations between p53 expression and age, TNM stage, lymph node metastasis (N classification), depth of invasion (T classification) or vascular invasion. In addition, the expression rates of p53 in ESCC of the Kazakh, Uygur and Han ethnic groups were 56.3, 53.6 and 53.7%, respectively. There was no significant difference in the expression of p53 protein among the different ethnicities (P\>0.05; data not shown).

In the TMA analysis, the positive expression rate of p53 protein was 58.1% (68/117) in cancer tissues and 11.3% (11/97) in adjacent normal tissues. This difference was statistically significant (P\<0.001). There was a significant association between p53 protein expression and the depth of invasion (P=0.011; [Table II](#tII-ol-0-0-11709){ref-type="table"}), but there was no significant difference in p53 protein expression between other clinicopathological factors, such as sex, age, TNM stage and lymph node metastasis ([Table II](#tII-ol-0-0-11709){ref-type="table"}).

### TP53 gene deletion and its associations with clinicopathological factors

FISH was performed in 214 of the 369 patients with complete follow-up data. The deletion rates of the *TP53* gene were 31.8% (68/214) in cancer tissue and 8.3% (2/24) in adjacent normal tissue, and the difference was statistically significant (P=0.01; [Fig. 2](#f2-ol-0-0-11709){ref-type="fig"}; [Table III](#tIII-ol-0-0-11709){ref-type="table"}). Among these, the *TP53* deletion rates in Kazakh, Uygur and Han ethic groups were 31.0, 36.1 and 28.2%, respectively; there was no significant difference when comparing the different ethnic groups (P\>0.05, data not shown). *TP53* gene deletion was significantly associated with tumor differentiation (P=0.002), lymph node metastasis (P=0.005) and vascular invasion (P\<0.001; [Table III](#tIII-ol-0-0-11709){ref-type="table"}). There were no significant associations between *TP53* gene deletion and other clinicopathological factors (P\>0.05).

In the TMA analysis, the deletion rates of the *TP53* gene were 47.9% (56/117) in cancer tissues and 2.1% (2/97) in adjacent normal tissues (P\<0.001). *TP53* gene deletion was significantly associated with lymph node metastasis (P=0.003) and TNM stage (P=0.01). However, there was no significant difference in *TP53* gene deletion between other clinicopathological factors (P\>0.05; [Table IV](#tIV-ol-0-0-11709){ref-type="table"}).

### Association between TP53 gene abnormalities and prognosis

Kaplan-Meier survival analysis was used to further analyze the relationship between *TP53* gene abnormalities and ESCC prognosis. There were no significant associations between p53 protein expression and the overall survival of patients with ESCC (P\>0.05, data not shown). However, *TP53* gene deletion was negatively associated with overall survival. Patients with *TP53* gene deletion had a worse prognosis (P\<0.05; [Fig. 3A](#f3-ol-0-0-11709){ref-type="fig"}). In addition, univariate Cox regression analysis demonstrated that *TP53* gene deletion, lymph node metastasis and vascular invasion were significantly associated with the overall survival of patients with ESCC (P\<0.05; [Table V](#tV-ol-0-0-11709){ref-type="table"}). Multivariate Cox analysis demonstrated that lymph node metastasis and vascular invasion were independent prognostic factors for ESCC.

In the TMA group, Kaplan-Meier analysis demonstrated that both p53 protein expression and *TP53* gene deletion were not associated with the overall survival of patients with ESCC. However, patients with the *TP53* gene deletion had a worse prognosis than those without the deletion ([Fig. 3B](#f3-ol-0-0-11709){ref-type="fig"}). In addition, univariate Cox regression analysis showed that the depth of invasion, lymph node metastasis and tumor differentiation were significantly associated with overall survival (P\<0.05; [Table VI](#tVI-ol-0-0-11709){ref-type="table"}). Furthermore, multivariate Cox analysis suggested that the depth of invasion and tumor differentiation were independent prognostic factors, patients with deeper invasion and lower differentiation had a worse prognosis.

### Concordance between the results of IHC and FISH

The χ^2^ test suggested that there was a significant association between the results of IHC and FISH (P=0.007). The positive concordance rate between IHC and FISH was 41.1% (39/95), the negative concordance rate was 75.6% (90/119), and the total concordance rate was 60.3% (129/214). There was also a significant association between IHC and FISH in the TMA analysis (P=0.001). The positive concordance rate of IHC and FISH was 60.3% (41/68), while the negative concordance rate was 69.4% (34/49), and the total concordance rate was 64.1% (75/117; [Table VII](#tVII-ol-0-0-11709){ref-type="table"}).

The present study also analyzed *TP53* gene deletion and protein expression in different stages of esophageal cancer ([Fig. 4](#f4-ol-0-0-11709){ref-type="fig"}). The positive rates of *TP53* gene deletion in normal esophageal mucosa, adjacent normal tissues, precancerous lesions, ESCC tissues and metastatic lesions of esophageal cancer were 0% (0/3), 2.1% (2/97), 30.8% (4/13), 47.9% (56/117) and 88.9% (8/9), respectively. The positive expression rates of p53 protein in these tissues were 0% (0/3), 11.3% (11/97), 46.2% (6/13), 58.1% (68/117) and 77.8% (7/9), respectively. There were significant differences in *TP53* gene deletion and protein expression when comparing the different histological stages (P\<0.05; [Table VIII](#tVIII-ol-0-0-11709){ref-type="table"}).

Discussion
==========

Mutations in p53 protein are carcinogenic and can promote the invasion, metastasis, proliferation and survival of tumors ([@b27-ol-0-0-11709]). The accumulation of p53 protein may indicate *TP53* gene mutation and detection of p53 protein accumulation by IHC can indirectly evaluate *TP53* gene mutation. However, IHC may miss *TP53* gene deletion ([@b20-ol-0-0-11709]). DNA FISH can directly detect the loss of the *TP53* gene locus, which is one of the main molecular features of the tumor suppressor gene variation and an important marker for the transformation of some normal cells.

The present study demonstrated that the positive rates of p53 protein expression in ESCC of in two groups, a multi-ethnic group and a TMA group, were 54.5 and 58.1%, respectively. It was also demonstrated that p53 protein expression was associated with tumor differentiation and depth of invasion, which indicated that the *TP53* mutation was not only related to the occurrence of ESCC, but also to prognostic factors such as malignant phenotype, invasion and metastasis, which were indirectly related to adverse prognosis. However, there was no significant association between p53 protein expression and other clinical factors, such as lymph node metastasis, TNM stage and overall survival, which was consistent with previous studies by Taghavi *et al* ([@b19-ol-0-0-11709]) and Yen *et al* ([@b28-ol-0-0-11709]). By contrast, previous studies have reported that mutated p53 protein could promote the invasion and metastasis of tumors and affect the prognosis of patients with ESCC ([@b15-ol-0-0-11709],[@b29-ol-0-0-11709],[@b30-ol-0-0-11709]). These conflicting results could be due to different patient selection processes, differences in the types of antibodies used and cut-ff values for p53 expression used in the different studies ([@b18-ol-0-0-11709],[@b31-ol-0-0-11709]).

The present study also detected p53 protein expression in Han, Uygur and Kazakh ethnic groups from Xinjiang, and identified that there were no significant differences in p53 protein expression among the three ethnicities, indicating that p53 protein expression was similar in patients with ESCC from different ethnic groups. In addition, the present results demonstrated that the expression of p53 protein was significantly associated with sex in the multi-ethnic group. However, the majority of previous studies on p53 suggested that there were no associations with sex ([@b15-ol-0-0-11709],[@b19-ol-0-0-11709],[@b28-ol-0-0-11709]). It was hypothesized that the present results could be an incidental anomaly due to the small sample size. The possible association between p53 and sex may be further confirmed by a larger sample size in future studies.

Moreover, the present study also detected TP53 gene deletion. *TP53* gene deletion rates were 31.8 and 47.9% in the tumor tissues of the multi-ethnic and the TMA groups, respectively. In addition, *TP53* gene deletion was also related to prognostic factors such as tumor differentiation and lymph node metastasis. In a previous study of p53 IHC and loss of heterozygosity (LOH) analysis with similar experimental conditions, including 94 resected ESCC samples, the *TP53* LOH rate was 67.5%, but it was not associated with the malignant phenotype of ESCC ([@b22-ol-0-0-11709]). In our previous study, FISH was used to detect *TP53* gene deletion in patients with ESCC of Kazakh background, which suggested that *TP53* gene deletion was related to tumor differentiation and lymph node metastasis ([@b32-ol-0-0-11709]). In the present study, additional ethnicities and samples were included, and *TP53* gene deletion was demonstrated to be more common in patients with poor differentiation, lymph node metastasis and vascular invasion at advanced stages, which was consistent with our previous study, suggesting that the altered *TP53* may play an important role in predicting the prognosis of ESCC. In addition, there was a significant association between *TP53* gene deletion and overall survival in multi-ethnic groups. Although there was no significant association between *TP53* gene deletion and overall survival in the TMA group, patients with *TP53* gene deletion displayed a tendency towards worse prognosis, compared with those without the deletion, which was consistent with the result of multi-ethnic groups. Overall, the present results suggested that *TP53* gene deletion was associated with poor prognosis and may be a potential and effective prognostic indicator of ESCC.

The expression rates of p53 protein were 54.5 and 58.1%, and the deletion rates of the *TP53* gene were 31.8 and 47.9% in the two groups, respectively. The total concordance rates of FISH and IHC for detecting *TP53* gene abnormality were 60.3 and 64.1%, respectively. When both methods were used simultaneously, the detection rate of *TP53* gene abnormalities was significantly increased. A previous study by Graesslin *et al* ([@b33-ol-0-0-11709]) reported that there was no significant association between *TP53* gene deletion and p53 protein expression in endometrial cancer, and there was no significant association between *TP53* gene deletion and clinical prognostic factors. Therefore, FISH was not recommended for the routine detection of the *TP53* gene in endometrial cancer ([@b33-ol-0-0-11709]). However, the present results support the combination of FISH and IHC in assessing *TP53* abnormalities in ESCC. Although FISH allows objective quantification of results by counting intranuclear signals, there are some disadvantages to this method, such as the influence of non-tumor cells on the results. However, the present study suggested that IHC combined with FISH could overcome this limitation.

In addition, the present study also detected *TP53* abnormalities in different stages of ESCC and found that *TP53* gene deletion and protein expression increased with the progression of ESCC. In a study of Barrett\'s esophagus, Davelaar *et al* ([@b34-ol-0-0-11709]) reported that the positive rates of *TP53* FISH and IHC increased with the progression of the disease, and the combined use of FISH and IHC technology could significantly improve the detection rate of *TP53* gene abnormalities at different stages of the disease, which is similar to the present results in ESCC. These results also indicated that *TP53* gene abnormalities are not only an early event of esophageal cancer, but also play an important role in tumor progression.

However, the sample size was relatively small and only one core of tumor tissue for each patient was included in TMA, which may account for the difference in the results observed between the TMA and the multi-ethnic group. Therefore, verification of the results with TMA, including larger sample size and more tumor cores is required in subsequent studies.

In conclusion, the present results demonstrated that the *TP53* gene mutation played an important role in the occurrence and development of ESCC. The factors affecting p53 overexpression are complex, and *TP53* gene deletion is one of the most important. These results suggested that FISH could be used as an additional method in the diagnosis of ESCC, especially when IHC results are negative. The application of FISH could increase the accuracy of chromosome karyotype determination, improve the detection efficiency of *TP53* gene abnormalities in ESCC, and help accurately evaluate the malignancy and prognosis of esophageal cancer.
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![p53 protein expression by immunohistochemistry. (A) Adjacent normal tissue. (B) Esophageal squamous cell carcinoma tissue. Magnification, ×10.](ol-20-02-1855-g00){#f1-ol-0-0-11709}

![Representative results of esophageal cancer samples detected using FISH showing *TP53* gene deletion (laser confocal). (A) Overlay, (B) TP53 signal and (C) chromosome 17 centromere signals. Blue arrows refer to the cells with TP53 gene deletion. Magnification, ×100. *TP53*, tumor protein 53; FISH, fluorescence *in situ* hybridization.](ol-20-02-1855-g01){#f2-ol-0-0-11709}
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![Tumor protein 53 protein expression and gene deletion status at different histological stages of ESCC. Magnification, IHC ×10, FISH ×100. ESCC, esophageal squamous cell carcinoma; FISH, fluorescence *in situ* hybridization; IHC, immunohistochemistry.](ol-20-02-1855-g03){#f4-ol-0-0-11709}

###### 

Association between p53 expression and clinicopathological characteristics of patients with ESCC.

                                   p53 expression                          
  -------------------------- ----- ---------------- ------------ --------- ---------
  Specimen                                                       152.682   \<0.001
    Adjacent normal tissue   187   2 (1.1)          185 (98.9)             
    ESCC                     369   201 (54.5)       168 (45.5)             
  Sex                                                            4.179     0.026
    Female                   112   70 (62.5)        42 (37.5)              
    Male                     257   131 (51.0)       126 (49.0)             
  Age, years                                                     1.658     0.119
    \>65                     145   85 (58.6)        60 (41.4)              
    ≤65                      224   116 (51.8)       108 (48.2)             
  TNM stage                                                      0.615     0.450
    I--II                    232   130 (56.0)       102 (44.0)             
    III                      137   71 (51.8)        66 (48.2)              
  T classification                                               0.739     0.226
    T1-T2                    145   83 (57.2)        62 (42.8)              
    T3-T4                    224   118 (52.7)       106 (47.3)             
  N classification                                               1.642     0.120
    No                       211   121 (57.3)       90 (42.7)              
    Yes                      158   80 (50.6)        78 (49.4)              
  Differentiation                                                3.904     0.032
    Good                     96    44 (45.8)        52 (54.2)              
    Moderate-poor            273   157 (57.5)       116 (42.2)             
  Tumor size                                                     3.484     0.074
    \<4                      204   120 (58.8)       84 (41.2)              
    ≥4                       165   81 (49.1)        84 (50.9)              
  Vascular invasion                                              0.049     0.893
    Negative                 294   161 (54.8)       133 (45.2)             
    Positive                 75    40 (53.3)        35 (45.7)              

ESCC, esophageal squamous cell carcinoma.

###### 

Association between p53 expression and clinicopathological characteristics of patients with ESCC (tissue microarray).

                                   p53 expression, IHC                        
  -------------------------- ----- --------------------- ----------- -------- ---------
  Specimen                                                           49.833   \<0.001
    Adjacent normal tissue   97    11 (11.3)             86 (88.7)            
    ESCC                     117   68 (58.1)             49 (41.9)            
  Sex                                                                0.035    0.509
    Female                   30    17 (56.7)             13 (43.3)            
    Male                     87    51 (58.6)             36 (41.4)            
  Age, years                                                         0.106    0.447
    \>60                     76    45 (59.2)             31 (40.8)            
    ≤60                      41    23 (56.1)             18 (43.9)            
  TNM stage                                                          0.337    0.347
    I--II                    56    31 (55.4)             25 (44.6)            
    III--IV                  61    37 (60.7)             24 (39.3)            
  T classification                                                   6.405    0.011
    T1-T2                    23    8 (34.8)              15 (65.2)            
    T3-T4                    94    60 (63.8)             34 (36.2)            
  N classification                                                   0.054    0.483
    No                       54    32 (59.3)             22 (40.7)            
    Yes                      63    36 (57.1)             27 (42.6)            
  Differentiation                                                    0.96     0.567
    Good                     26    15 (57.7)             11 (42.3)            
    Moderate-poor            91    53 (58.2)             38 (41.8)            

ESCC, esophageal squamous cell carcinoma; IHC, immunohistochemistry.

###### 

Association between p53 gene deletion and clinicopathological characteristics of patients with ESCC.

                             p53 FISH                          
  -------------------------- ----------- ------------ -------- ---------
  Specimen                                            5.712    0.01
    Adjacent normal tissue   2 (8.3)     22 (91.7)             
    ESCC                     68 (31.8)   146 (68.2)            
  Sex                                                 0.051    0.872
    Female                   19 (30.6)   43 (69.4)             
    Male                     49 (32.2)   103 (67.8)            
  Age, years                                          1.653    0.224
    \>60                     29 (37.2)   49 (62.8)             
    ≤60                      39 (28.7)   97 (71.3)             
  TNM stage                                           3.23     0.089
    I--II                    39 (27.7)   102 (72.3)            
    III                      29 (39.7)   44 (60.3)             
  T classification                                    0.043    0.881
    T1-T2                    26 (31.0)   58 (69.0)             
    T3-T4                    42 (32.3)   88 (67.7)             
  N classification                                    7.278    0.005
    No                       30 (24.4)   93 (75.6)             
    Yes                      38 (41.8)   53 (58.2)             
  Differentiation                                     8.963    0.002
    Good                     11 (17.2)   53 (82.8)             
    Moderate-Poor            57 (38.0)   93 (62.0)             
  Tumor size                                          0.273    0.66
    \<4                      38 (33.3)   76 (66.7)             
    ≥4                       30 (30.0)   70 (70.0)             
  Vascular invasion                                   16.274   \<0.001
    Negative                 45 (25.7)   130 (74.3)            
    Positive                 23 (59.0)   16 (41.0)             

ESCC, esophageal squamous cell carcinoma

###### 

Association between p53 gene deletion and clinicopathological characteristics of patients with ESCC (tissue microarray).

                                   p53 FISH                        
  -------------------------- ----- ----------- ----------- ------- ---------
  Specimen                                                 56.31   \<0.001
    Adjacent normal tissue   97    2 (2.1)     95 (97.9)           
    ESCC                     117   56 (47.9)   61 (52.1)           
  Sex                                                      0.484   0.487
    Male                     87    40 (46)     47 (54)             
    Female                   30    16 (53.3)   14 (46.7)           
  Age, years                                               1.506   0.22
    ≤60                      40    16 (40)     24 (60)             
    \>60                     77    40 (51.9)   37 (48.1)           
  N classification                                         8.484   0.003
    No                       54    18 (33.3)   36 (66.7)           
    Yes                      63    38 (60.3)   25 (39.7)           
  T classification                                         0.008   0.557
    T1-T2                    23    11 (47.8)   12 (52.2)           
    T3-T4                    94    45 (47.9)   49 (52.1)           
  TNM stage                                                6.353   0.01
    I--II                    56    20 (35.7)   36 (64.3)           
    III--IV                  61    36 (41.0)   25 (59.0)           
  Differentiation                                          1.184   0.194
    Good                     26    10 (38.5)   16 (61.5)           
    Moderate-poor            91    46 (50.5)   45 (49.5)           

ESCC, esophageal squamous cell carcinoma; FISH, fluorescence *in situ* hybridization.

###### 

Univariate and multivariate analysis of overall survival in patients with esophageal squamous cell carcinoma.

                                             Univariate analysis    Multivariate analysis                          
  ------------------------------------------ ---------------------- ----------------------- ---------------------- ---------
  Sex, female vs. male                       1.271 (0.843--1.918)   0.252                                          
  Age, ≤60 vs. \>60 years                    1.365 (0.955--1.952)   0.087                                          
  T classification, T1-T2 vs. T3-T4          1.335 (0.926--1.925)   0.121                                          
  N classification, negative vs. positive    2.336 (1.630--3.348)   \<0.001                 0.500 (0.341--0.733)   \<0.001
  Differentiation, good vs. moderate-poor    1.229 (0.964--1.569)   0.097                                          
  Tumor size, \<4 cm vs. ≥4 cm               1.116 (0.785--1.587)   0.54                                           
  Vascular invasion, negative vs. positive   2.386 (1.585--3.593)   \<0.001                 0.563 (0.363--0.874)   0.01
  p53 FISH, negative vs. positive            1.457 (1.009--2.105)   0.04                    0.863 (0.589--1.265)   0.45
  p54 IHC, negative vs. positive             1.122 (0.785--1.603)   0.527                                          

FISH, fluorescence *in situ* hybridization; IHC, immunohistochemistry; HR, hazard ratio.

###### 

Univariate and multivariate analysis of overall survival in patients with esophageal squamous cell carcinoma (tissue microarray).

                                            Univariate analysis    Multivariate analysis                          
  ----------------------------------------- ---------------------- ----------------------- ---------------------- -------
  Sex, female vs. male                      1.842 (1.043--3.254)   0.035                   0.728 (0.446--1.187)   0.203
  Age, ≤60 vs. \>60 years                   0.990 (0.615--1.594)   0.967                                          
  T classification, T1-T2 vs. T3-T4         0.339 (0.155--0.745)   0.007                   1.925 (1.073--3.451)   0.028
  N classification, negative vs. positive   0.544 (0.340--0.871)   0.011                   0.449 (0.201--1.007)   0.052
  Differentiation, good vs. moderate-poor   0.295 (0.150--0.580)   \<0.001                 0.324 (0.162--0.646)   0.001
  p53 FISH, negative vs. positive           0.701 (0.445--1.105)   0.126                                          
  p53 IHC, negative vs. positive            1.117 (0.705--1.770)   0.638                                          

FISH, fluorescence *in situ* hybridization; IHC, immunohistochemistry; HR, hazard ratio.

###### 

Concordance between the results of IHC and FISH in esophageal squamous cell carcinoma.

  A, Multi ethnic group                                          
  -------------------------- ----------------- ----------------- -------------------------
  Negative                   29                90                75.6
  Positive                   39                56                41.1
  Total                      68                146               60.3
                                                                 
  **B, Tissue microarray**                                       
                             **p53 FISH**                        
                                                                 
  **p53 IHC**                **Positive, %**   **Negative, %**   **Concordance rate, %**
                                                                 
  Negative                   15                34                69.4
  Positive                   41                27                60.3
  Total                      56                61                64.1

FISH, fluorescence *in situ* hybridization; IHC, immunohistochemistry.

###### 

p53 abnormalities detected by FISH and IHC at different histological stages.

  A, FISH                                                              
  -------------------------- ------- ------------------ -------------- -------------
  Normal esophageal mucosa   3       0                  3              
  Adjacent normal tissue     97      2 (2.1)            95             
  Precancerous lesion        13      4 (30.8)           9              \<0.001
  ESCC tissue                117     56 (47.9)          61             
  Metastatic lesion          9       8 (88.9)           1              
                                                                       
  **B, IHC**                                                           
                                                                       
                                     **p53**                           
                                                                       
  **Histology**              **n**   **Positive (%)**   **Negative**   **P-value**
                                                                       
  Normal esophageal mucosa   3       0                  3              
  Adjacent normal tissue     97      11 (11.3)          86             
  Precancerous lesion        13      6 (46.2)           7              \<0.001
  ESCC tissue                117     68 (58.1)          49             
  Metastatic lesion          9       7 (77.8)           2              
                                                                       
  **C, FISH and IHC**                                                  
                                                                       
                                     **p53**                           
                                                                       
  **Histology**              **n**   **Positive (%)**   **Negative**   **P-value**
                                                                       
  Normal esophageal mucosa   3       0                  3              
  Adjacent normal tissue     97      13 (13.4)          84             
  Precancerous lesion        13      9 (69.2)           4              \<0.001
  ESCC tissue                117     83 (70.9)          34             
  Metastatic lesion          9       8 (88.9)           1              

ESCC, esophageal squamous cell carcinoma; FISH, fluorescence *in situ* hybridization; IHC, immunohistochemistry.
